Pino, C., Lee, M. W., Anderson, Z. S., Masjedi, A. D., Yu, E., Furey, K. B., Muderspach, L. I., Roman, L. D., Wright, J. D., & Matsuo, K. (2024). Temporal trends of adolescents and young adults (AYA) with gynecologic malignancy in the United States. Gynecologic Oncology Reports, 54, 101455. https://doi.org/10.1016/j.gore.2024.101455

Gordhandas, S., Da Cruz Paula, A., Kertowidjojo, E. C., Pareja, F., Dessources, K., da Silva, E. M., Derakhshan, F., Mueller, J. J., Abu-Rustum, N. R., Chui, M. H., & Weigelt, B. (2024). Molecular profiling of primary endometrioid endometrial cancer and matched lung metastases: CTNNB1 mutation as a potential driver. Gynecologic Oncology Reports, 53, 101391. https://doi.org/10.1016/j.gore.2024.101391

Knisely, A., Huang, Y., Li, Y., Prabhu, V. S., & Wright, J. D. (2022). Adjuvant and first line chemotherapy use for endometrial cancer. Gynecologic Oncology Reports, 41, 101002. https://doi.org/10.1016/j.gore.2022.101002

Praiss, A., Navitski, A., Cohen, S., Tessier-Cloutier, B., Broach, V., & O’Cearbhaill, R. E. (2022). Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines. Gynecologic Oncology Reports, 41, 100982. https://doi.org/10.1016/j.gore.2022.100982

Navitski, A., Al-Rawi, D. H., Liu, Y., Rubinstein, M. M., Friedman, C. F., Rampal, R. K., Mandelker, D. L., Cadoo, K., & O’Cearbhaill, R. E. (2021). Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer. Gynecologic Oncology Reports, 38, 100873. https://doi.org/10.1016/j.gore.2021.100873